---
layout: post
title: "Generic Drug User Fee Rates for Fiscal Year 2023"
date: 2026-02-05 19:01:05 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-22099
original_published: 2022-10-12 00:00:00 +0000
significance: 8.00
---

# Generic Drug User Fee Rates for Fiscal Year 2023

**Published:** February 05, 2026 19:01 UTC
**Source:** Federal Register
**Original Published:** October 12, 2022 00:00 UTC
**Document Number:** 2022-22099

## Summary

The Federal Food, Drug, and Cosmetic Act (FD&C Act or statute), as amended by the Generic Drug User Fee Amendments of 2022 (GDUFA III), authorizes the Food and Drug Administration (FDA, Agency, or we) to assess and collect fees for abbreviated new drug applications (ANDAs); drug master files (DMFs); generic drug active pharmaceutical ingredient (API) facilities, finished dosage form (FDF) facilities, and contract manufacturing organization (CMO) facilities; and generic drug applicant program user fees. In this document, FDA is announcing fiscal year (FY) 2023 rates for GDUFA III fees. These fees are effective on October 1, 2022, and will remain in effect through September 30, 2023.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/10/12/2022-22099/generic-drug-user-fee-rates-for-fiscal-year-2023)
- API: https://www.federalregister.gov/api/v1/documents/2022-22099

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
